Skip to main content

Genome Quebec Funds VIA's PGx Study in Clinical Trials for ACS Drug

NEW YORK (GenomeWeb News) - VIA Pharmaceuticals said today that it has secured funding from Genome Quebec to perform a pharmacogenomics sub-study as part of clinical trials for its lead candidate for acute coronary syndrome.
VIA said it will collaborate with the Montreal Heart Institute to perform genomics and proteomics studies and develop a genotyping panel it could use in Phase II clinical trials for its ACS drug VIA-2291.
VIA, a San Francisco-based small-molecule drug developer, estimated that the program will cost around $5 million. The company will provide around $2.4 million in funding for the ACS clinical trial, and around $200,000 for costs related to the pharmacogenomics sub-study. Genome Quebec and other companies will provide the balance of the funding, the company said.
The project will focus on development of a 5 lipoxygenase genotyping panel and an ADME/tox panel for VIA-2291, VIA said.
"We believe that this sub-study will generate important information on the pharmacogenomics of our study patients, and will provide additional insight into the role we believe VIA-2291 will play in reducing vascular inflammation in ACS patients with atherosclerosis," VIA CEO Lawrence Cohen said in a statement.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.